AZ's Alexion Acquisition Looks Astute Bit Of Business

Offers $39bn For Rare Disease Drug Pioneer

 
• By Kevin Grogan

Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.

Sodertalje, Sweden - April 27, 2014: Three purple flags with the logo for Atrazeneca flying in the wind on top of the flagpoles against the blue sky.
aSTRAzENECA FLAGS UP PROMISE OF aLEXION'S RARE DISEASE DRUGS • Source: Archive

More from Deals

More from Business